Aromatic amino acids in the brain function as precursors for the monoamine neurotransmitters serotonin (substrate tryptophan) and the catecholamines [dopamine, norepinephrine, epinephrine; substrate tyrosine (Tyr)]. Unlike almost all other neurotransmitter biosynthetic pathways, the rates of synthesis of serotonin and catecholamines in the brain are sensitive to local substrate concentrations, particularly in the ranges normally found in vivo. As a consequence, physiologic factors that influence brain pools of these amino acids, notably diet, influence their rates of conversion to neurotransmitter products, with functional consequences. This review focuses on Tyr and phenylalanine (Phe). Elevating brain Tyr concentrations stimulates catecholamine production, an effect exclusive to actively firing neurons. Increasing the amount of protein ingested, acutely (single meal) or chronically (intake over several days), raises brain Tyr concentrations and stimulates catecholamine synthesis. Phe, like Tyr, is a substrate for Tyr hydroxylase, the enzyme catalyzing the rate- Apart from their roles as constituents of protein, the only other known functions of the aromatic amino acids in brain are as precursors for the monoamine neurotransmitters, serotonin and the catecholamines [dopamine (DA), 8 norepinephrine (NE), and epinephrine]. This latter biochemical link is of interest, because the rates of synthesis and release of these transmitters are directly modified by the brain concentrations of their amino acid precursors, tryptophan (5HT) and phenylalanine (Phe) and tyrosine (Tyr; catecholamines), which in turn are influenced by their availability from blood (1). As a result, physiologic and pathophysiologic factors that influence blood concentrations of these amino acids and others that compete with them for a common transporter across the blood brain barrier [the large neutral amino acids (LNAA)] predictably alter aromatic amino acid concentrations in brain, the formation and release of these monoamine transmitters, and consequently brain function (1,2). This review will consider the evidence that precursor supply modifies monoamine production and the physiologic factors that influence this relation, focusing on the Tyr-catecholamine relation. Consideration will be given to the role of Phe in catecholamine synthesis in support of the idea that this amino acid functions as a cosubstrate with Tyr for Tyr hydroxylase (TH) and is not an inhibitor of this enzyme in vivo at normal and even high concentrations. Brain functions influenced by Tyr-mediated changes in catecholamine synthesis will also be discussed.
Apart from their roles as constituents of protein, the only other known functions of the aromatic amino acids in brain are as precursors for the monoamine neurotransmitters, serotonin and the catecholamines [dopamine (DA), 8 norepinephrine (NE), and epinephrine]. This latter biochemical link is of interest, because the rates of synthesis and release of these transmitters are directly modified by the brain concentrations of their amino acid precursors, tryptophan (5HT) and phenylalanine (Phe) and tyrosine (Tyr; catecholamines), which in turn are influenced by their availability from blood (1) . As a result, physiologic and pathophysiologic factors that influence blood concentrations of these amino acids and others that compete with them for a common transporter across the blood brain barrier [the large neutral amino acids (LNAA)] predictably alter aromatic amino acid concentrations in brain, the formation and release of these monoamine transmitters, and consequently brain function (1, 2) . This review will consider the evidence that precursor supply modifies monoamine production and the physiologic factors that influence this relation, focusing on the Tyr-catecholamine relation. Consideration will be given to the role of Phe in catecholamine synthesis in support of the idea that this amino acid functions as a cosubstrate with Tyr for Tyr hydroxylase (TH) and is not an inhibitor of this enzyme in vivo at normal and even high concentrations. Brain functions influenced by Tyr-mediated changes in catecholamine synthesis will also be discussed. decarboxylated to DA by aromatic L-amino acid decarboxylase. In neurons that use DA as a transmitter, no further enzymatic modification occurs. Neurons that use NE as a transmitter contain an additional enzyme, DA-b-hydroxylase, that converts DA to NE. Neurons using epinephrine as a transmitter contain 1 additional enzyme, phenylethanolamine-N-methyl transferase, which is responsible for catalyzing the conversion of NE to epinephrine. The initial step in the pathway, Tyr hydroxylation, is rate limiting and thus controls the rate of synthesis through the entire pathway (3, 4) . Early work established that this enzyme was subject to end-product inhibition (by any of the above products) as examined either in vitro using enzyme preparations (4) or in vivo, such as by following the rate of 14 C-Tyr conversion to 14 Ccatecholamine in the brains of rats treated with a drug to raise endogenous catecholamine concentrations (e.g. a monoamine oxidase inhibitor) (5) . Later work established that TH was subject to a number of other controls, including a rapid phosphorylationlinked activation of enzyme during periods of increased neuronal activity (6) (i.e. synthesis increases at times of greater neuronal demand).
The idea that precursor (Tyr) concentrations might directly influence the rate of Tyr hydroxylation and catecholamine production did not seem promising, because published values for the substrate K m were below normal brain Tyr concentrations [i.e. the enzyme was thought to be close to substrate saturation; see (2) ]. However, a study then demonstrated that raising brain Tyr concentrations (by injecting the amino acid) could rapidly stimulate DOPA synthesis in rat brain (7) . This finding suggested that Tyr concentrations in the vicinity of TH must be well below saturation levels. A subsequent refinement of this observation was that at least in DA neurons neuronal activation was required to observe a precursor-linked stimulation of DA synthesis. For example, Tyr administration could stimulate DA synthesis in the corpus striatum (the site of a major projection of terminals from DA cell bodies in the substantia nigra), but pretreatment of animals with a DA receptor antagonist to activate the neurons was required (8) . A physiological demonstration of the requirement for neuronal activation is supplied by DA neurons in the rat retina. The retina contains a population of DA interneurons that is light sensitive; they are relatively inactive in darkness and become active in the light. In association with neuronal activation is an activation of TH (9) . If activation is normally required for Tyr administration to stimulate Tyr hydroxylation rate, then Tyr injection should enhance hydroxylation rate in retinas during the day but not during night. Such an effect is illustrated in Table 1 . In this study, Tyr administration raised retinal Tyr levels in light-and dark-adapted rats but increased retinal hydroxylation rate only in the light-exposed retina. (Hydroxylation rate is indicated as DOPA concentration in Table 1 and represents the accumulation of this hydroxylation product 30 min after rats received a drug that inhibits the conversion of DOPA to DA. Normally, DOPA concentrations are extremely low and accumulate linearly for at least 30 min after drug administration, providing a good in vivo estimate of hydroxylation rate (10, 11) and, thus, of the overall rate of catecholamine synthesis, because the hydroxylation step is rate limiting in the pathway (11, 12) ).
The retina also proved useful for demonstrating that increases in local Tyr concentrations produced by a physiological means (food ingestion) could stimulate DOPA synthesis. The ingestion of a protein-containing meal was known to produce a rapid increase in Tyr concentrations in the brain (13) . Because LNAA transport across the blood-retinal barrier is similar to that across the blood-brain barrier (BBB) (14) , the presumption was that a protein meal would also raise retinal Tyr concentrations. Hence, a study was undertaken to examine whether the ingestion of a protein-containing meal by rats would elevate retinal Tyr concentrations and if so, stimulate DOPA synthesis in the light but not the dark ( Table 2 ). The ingestion of the protein (but not the carbohydrate) meal was observed to raise retinal Tyr concentrations .3-fold, a rise similar to that observed when Tyr was injected (Table 1) . In association with this rise, DOPA synthesis doubled (Table 2) . Whereas Tyr levels also increased when the protein meal was ingested during darkness, no increase in DOPA synthesis resulted (15) . Hence, Tyr hydroxylation (DOPA synthesis) rate in retina increased in response to an increase in local Tyr concentrations that were produced physiologically (by a protein meal) in neurons that have been activated physiologically (by light).
Tyr concentrations in the brain are influenced by protein ingested not only in a single meal. They are also affected when the protein content of the diet is modified over several days or more (16, 17) . Because the magnitude of difference between brain Tyr concentrations in rats chronically ingesting different levels of dietary protein was observed to be 2-fold or more and thus similar to that influencing DOPA synthesis when rats ingest a single, protein-containing meal, we evaluated if DOPA synthesis would be predictably influenced by chronic changes FIGURE 1 Brain Tyr uptake and DA and NE synthesis in neurons. Tyr is converted to DA and NE in neurons containing TH (*), the enzyme catalyzing the rate-limiting step in catecholamine synthesis. Tyr concentration controls synthesis (in active neurons), because the enzyme appears normally to be unsaturated with Tyr. Brain Tyr uptake influences brain Tyr levels and thus catecholamine synthesis. Brain Tyr uptake depends on the serum levels of Tyr and its LNAA competitors for transport at the BBB (revolving door). Meals and diet affect DA and NE synthesis by directly influencing serum levels of Tyr and the other LNAA and thus brain Tyr uptake and levels. MOPEG-SO 4 , 3-methoxy-4-hydroxyphenylethyleneglycol-sulfate, a major NE metabolite in rat brain. Reproduced from (59) . Table 3) . Hence, retinal Tyr levels and DOPA synthesis varied with dietary protein content chronically as well as acutely. In addition, when we measured these same variables in hypothalamus, a portion of the brain intimately involved in food-intake regulation, we observed effects that were similar to those in retina. That is, hypothalamic Tyr concentrations rose significantly (about double) between 2 and 10% protein and DOPA synthesis rose ;50% over this range of protein intakes (Table 3) . A number of points should be made from these observations. First, variations in Tyr supply affect not just Tyr hydroxylation (DOPA synthesis) rate; studies by others indicate that they affect overall catecholamine production and release (19) (20) (21) , suggesting functional consequences. Second, because DOPA synthesis varied directly with Tyr level in hypothalamus, the bulk of the catecholamine terminals in hypothalamus must be active under the conditions examined. Third, unlike the retina in which the dominant catecholamine is DA, hypothalamus contains terminals of DA, NE, and epinephrine neurons. Hence, whereas an effect on DOPA synthesis in the retina implies an action in DA neurons, an effect on DOPA synthesis in hypothalamus could be in any or all of the catecholamine terminals in this region. At present, we do not know which catecholamine neurons are affected. And fourth, although it is unclear why retinal DA neurons should be sensitive to dietary protein ingestion via effects on local Tyr concentrations, it is of interest physiologically that such an effect occurs on hypothalamic catecholamine nerve terminals, because these neurons are involved in appetite control (22) . What might the connection be? One speculation relates to dietary protein adequacy in animals (including humans) that occupy environments in which protein availability normally varies markedly, requiring them to be able to sense and obtain adequate protein supplies. In mature rats, the maintenance protein requirement is 5-7% (percent energy) (23) . The range of protein intake that is associated with a linear relation to hypothalamic Tyr levels and DOPA synthesis is 2-10%, a range that brackets the maintenance protein requirement. Conceivably, therefore, the changes in Tyr levels and DOPA (and overall catecholamine) synthesis produced in hypothalamus (and perhaps elsewhere in the brain) by the ingestion of different levels of dietary protein could be a signal to appetite control circuitry regarding dietary protein adequacy. In nature, animals experience circadian and circannual variations in dietary protein intake. For example, nonhuman primates, studied in their natural environments, have been shown to vary above and below their protein requirement, depending on the time of year and the availability of protein sources in the environment (24) . Moreover, although data are more limited, rats in their native habitats appear to consume protein in amounts that place their intakes modestly above requirement levels (25) . In natural environments, mechanisms that provide information to the brain regarding dietary protein status would be extremely useful in helping animals to optimize foraging efficiency to ensure adequacy of protein intake over time.
Phe and catecholamine synthesis When TH was initially purified and characterized (in brain and adrenal) and its kinetic properties studied in vitro using a synthetic pterin cofactor (6,7-dimethyltetrahydropterin), the enzyme was found to hydroxylate Phe, but only at a small fraction of the rate at which it hydroxylated Tyr (26). In addition, Phe was observed to inhibit Tyr hydroxylation (26) . When subsequently examined using the natural pterin cofactor, tetrahydrobiopterin, the enzyme was found to hydroxylate Phe at a rate comparable to that of Tyr. Moreover, whereas Tyr was found to inhibit enzyme activity at high concentrations (dubbed substrate inhibition), Phe did not show this effect (27) . The investigators were surprised by the extent to which TH could hydroxylate Phe and wondered if Phe might not be the preferred substrate for the enzyme. And, in light of the findings, they also questioned whether the reduction in catecholamines reported in subjects with classical phenylketonuria (PKU), who have extremely high Phe concentrations in blood and tissues, was due to Phe inhibition of TH (27) . Subsequently, the hydroxylation of radioactively labeled Phe to DOPA was demonstrated in synaptosomes (a preparation of nerve endings) from brain tissue and linked directly to TH [because the effect was blocked by pretreatment of synaptosomes with a known TH inhibitor and Phe hydroxylase is not present in brain (28, 29) ]. Suggestive evidence also exists that Tyr was the preferred substrate (29) (30) (31) . If Phe is as good a substrate for TH as is Tyr, has a K m for the enzyme that is in the range of that for Tyr (29) and also in the range of Phe concentrations found in vivo, and shows no substrate inhibition, then raising Phe concentrations in vivo in the brain might stimulate DOPA synthesis in a manner similar to that seen in response to raising Tyr concentrations (10) . We studied this possibility using the retinal DA model system in which Tyr administration rapidly stimulates DOPA synthesis (Tyr hydroxylation) in light-adapted rats (10) . However, in normal rats, Phe administration leads to an immediate rise in circulating Tyr concentrations (the result of an active Phe hydroxylating capacity in liver), causing retinal Phe and Tyr levels to rise. Because a rise in retinal Tyr stimulates DOPA synthesis, a convincing evaluation of the ability of an increase in retinal Phe to enhance DOPA synthesis could not be conducted in normal animals. This complication, however, was eliminated by pretreating rats with an inhibitor of Phe hydroxylase, p-chlorophenylalanine. In such animals, an injection of Phe was found to increase retinal Phe but not Tyr concentrations ( Table 4) . Of particular interest, while a large rise in retinal Tyr concentrations, produced by injecting this amino acid, stimulated DOPA synthesis in p-chlorophenylalanine-pretreated rats, a similarly large rise in retinal Phe failed to stimulate DOPA synthesis (Table 4 ) (32). This finding is somewhat surprising but might be explicable if Tyr were the preferred substrate for the hydroxylase enzyme. As noted above, this possibility was suggested by work in synaptosomes, showing that Tyr more effectively inhibited labeled Phe conversion to labeled DOPA than did Phe labeled Tyr to labeled DOPA (29, 30) .
To examine this possibility further, we turned to a different model system, the PC-12 cell. This model was preferred, because intracellular Phe and Tyr concentrations could be more easily and independently varied than in animals and the interactions between Phe and Tyr on DOPA synthesis more easily quantitated. Moreover, the intact cellular system seemed likely to provide a more natural milieu in which to study the enzyme than an in vitro incubation using an enzyme preparation. The PC-12 cell is a standard model system for studying catecholamine synthesis in nervous tissue (33) and its TH behaves in a manner like that observed in vivo in neurons (34) . In these studies, PC-12 cells were incubated for 45 min in the presence of a labeled amino acid (either 3 H-Phe or 3 H-Tyr) and unlabeled amino acids (Phe and/or Tyr) along with an inhibitor of DOPA conversion to DA (m-hydroxybenzylhydrazine, the same drug used in vivo). At the end of the incubation period, the cells and media were harvested for assay of labeled and unlabeled amino acids (Tyr, Phe, and DOPA, using separation by HPLC and quantitation by scintillation counting of fractions and on-line electrochemical detection or o-phthalaldehyde fluorescence) (35) . Figure 2 plots the results of a study in which 3 H-DOPA synthesis from 3 H-Phe was examined in the presence of varying concentrations of unlabeled Tyr and Phe. Figure 3 plots the results of a similar study in which 3 H-DOPA synthesis from 3 H-Tyr was examined. First, in Figure 2, H-Phe, with synthesis rates being much greater in depolarizing (black circles; incubated in medium containing 56 mmol/L potassium) than in quiescent cells (white circles; incubated in medium containing 4.8 mmol/L potassium). No Tyr has been added to the medium in these dishes.
3 H-DOPA synthesis increases as medium Phe concentration rises from 0 to 30 mmol/L and then plateaus (no substrate inhibition is apparent). Measurements of intracellular Phe concentration and specific activity indicated a K m value between 40 and 90 mmol/L. In vivo, brain Phe concentrations typically range between 50 and 100 mmol/L (13). Total DOPA synthesis in these dishes (panel A) shows the same relation to medium Phe concentrations. If these incubations were then conducted in the presence of step-wise increasing concentrations of unlabeled Tyr ranging from 1 to 100 mmol/L, the appearance of 3 H-DOPA from 3 H-Phe dropped progressively as Tyr concentration increased, such that at 100 mmol/L Tyr, essentially no 3 H-DOPA was produced from 3 H-Phe (Fig. 2, right panels) . However, even as DOPA synthesis from Phe was suppressed, total DOPA synthesis (Fig. 2, left panels) was not falling until the highest Tyr medium concentration was achieved, suggesting that the enzyme preferred Tyr as a substrate (particularly because intracellular Phe concentrations were not influenced appreciably by media Tyr concentrations) (35) . Moreover, where some inhibition of total DOPA synthesis occurred at 100 mmol/L Tyr (suggestive of Tyr substrate inhibition) at low medium Phe concentrations (below 10 mmol/L), Tyr appeared not to inhibit DOPA synthesis at higher medium Phe concentrations. This latter effect probably reflects the fact that as medium Figure 3A ,B, which represents results from dishes containing no added Phe, both 3 H-and cold DOPA synthesis rose as medium Tyr increased (in dishes containing a high potassium concentration), reaching a peak at 10 mmol/L Tyr. At higher medium Tyr concentrations, DOPA synthesis declined, suggestive of substrate inhibition. From measurements of intracellular Tyr concentrations and specific activity, the K m value for Tyr was estimated to be ;25 mmol/L, a value similar to that observed by others (34) . In comparison, brain Tyr concentrations in vivo typically vary between 50 and 200 mmol/L (13) ( Table 3) . When incubations are then conducted in the presence of different concentrations of unlabeled Phe, ranging from 1 to 300 mmol/L, the appearance of 3 H-DOPA from 3 H-Tyr does not begin to drop until Phe concentrations reach 60 mmol/L (Fig. 3H) . And, although suppression of 3 H-DOPA synthesis from 3 H-Tyr is notable at 60 and 300 mmol/L, it is not complete, and indeed, at 100 mmol/L Tyr, DOPA synthesis from Tyr accounts for almost by guest on August 15, 2017 jn.nutrition.org 100% of total DOPA synthesis (compare panels I and J of Fig. 3 at 100 mmol/L Tyr). It should also be noted in the left panels of Figure 3 that as medium Phe concentration rises, no inhibition of DOPA synthesis is evident; indeed, the addition of Phe raises DOPA synthesis at low medium Tyr concentrations and also at high medium Tyr concentrations (compare panels A and I in Fig. 3 ). As noted above, at high medium Tyr concentrations, Phe probably has this effect by blocking cellular Tyr uptake, thereby keeping intracellular Tyr concentrations low (35) .
From these results in PC-12 cells, we can hazard an interpretation of the findings in the animal studies in which Phe injection appeared to have no effect on retinal DOPA synthesis (Table 4) . First, normal retinal Phe and Tyr concentrations are in the 2-4 nmol/mg protein range, which is ;400 mmol/L Phe and 300 mmol/L Tyr (calculated from data in Table 4 ). When retinal Phe is increased 3-fold by Phe injection (to ;1200 mmol/L), no increase in DOPA synthesis is evident. From the PC-12 cell studies, intracellular Phe concentrations reach ;1100 mmol/L when medium Phe concentration is 300 mmol/L (35). Intracellular Tyr concentrations approximate 300 mmol/L when medium Tyr concentrations are between 10 and 100 mmol/L in the presence of 300 mmol/L Phe (35) . From Figure 2H ,J, it is clear that at these concentrations of Phe and Tyr very little DOPA is being synthesized from Phe. Hence, if a comparison between PC-12 cells and retina is valid, almost all DOPA synthesized in retina is derived from Tyr at normal retinal Tyr concentrations regardless of the retinal Phe concentration. Accordingly, variations in retinal Phe would be predicted to have little impact on total DOPA synthesis in retina. However, it should be noted that if the same analysis is applied to the stimulation of retinal DOPA synthesis by an injection of Tyr, which raises retinal Tyr concentrations from ;3-13 nmol/mg protein (;300-1200 mmol/L) in the presence of 300-400 mmol/L Phe (Table 4) , the PC-12 cell results do not predict stimulation of DOPA synthesis by Tyr. That is, 300-400 mmol/L intracellular Phe is obtained when medium Phe concentrations are ;60 mmol/L. An increase from 300 to 1200 mmol/L intracellular Tyr occurs when medium Tyr is raised from 10 to 100 mmol/L (35). However, total DOPA synthesis declines when medium Tyr is increased from 10 to 100 mmol/L at a medium Phe concentration of 60 mmol/L (Fig. 3G) , which clearly stands in contrast to the rise in retinal DOPA synthesis produced by Tyr injection (Table 4) . A satisfactory explanation for this difference is lacking. Indeed, more generally, if substrate inhibition by Tyr is a real phenomenon in vivo, no satisfactory explanation with supporting data to our knowledge has yet been offered that indicates why raising Tyr concentrations (whether by injection or via the diet) can accelerate catecholamine synthesis (and release) by neurons. Moreover, if the K m of TH for Tyr is ;25 mmol/L (see above), normal tissue Tyr concentrations are 50-200 mmol/L, and Tyr levels producing a rise in Tyr hydroxylation rate in activated neurons reach 1,000 mmol/L or more, it is difficult to imagine how this rise in substrate level could enhance the degree of Tyr saturation of TH sufficiently to produce this effect, because the enzyme should already be almost fully saturated. One hypothesis might be that the local intracellular Tyr pool available to TH differs from and is lower than that elsewhere in the neuron (e.g. when the neurons and TH are activated, Tyr utilization by TH increases markedly and local Tyr concentrations fall) (10), although this possibility has not been carefully evaluated.
Finally, it is of interest to consider whether and under what conditions Phe can inhibit Tyr hydroxylation (DOPA synthesis). In the rat retinal study discussed above (32), a Phe-DOPA synthesis dose-response study was also conducted and a significant inhibition of retinal DOPA synthesis was observed at a retinal Phe concentration of 1660 mmol/L. This concentration exceeds that reached in the PC-12 cell studies discussed above, making them of no use in assessing if substrate inhibition has emerged at such high Phe concentrations. But in recent studies assessing brain Phe concentrations in the brains of subjects with classical PKU (homozygous) using magnetic resonance spectroscopy, Phe concentrations ranged to only 900 mmol/L (36). These concentrations are considerably lower than those associated with inhibition of DOPA synthesis in retina. Hence, this comparison supports the notion advanced previously by Kaufman and associates (27) that if PKU is associated with diminished catecholamine synthesis, the effect may be unrelated to a direct inhibition of TH by Phe.
Functional effects of Tyr-induced changes in catecholamine synthesis Because Tyr administration stimulates catecholamine synthesis in the brain, a number of functions have been examined that might be anticipated to be affected, including blood pressure and the secretion of pituitary hormones. Dosing with the amino acid was found to reduce blood pressure in hypertensive rats (37) and to inhibit the secretion of the pituitary hormone prolactin in rats pretreated with reserpine (38) , both expected effects based on a stimulation of NE and DA synthesis/release, respectively. Tyr administration has also been reported to improve working memory under stressful conditions in humans, an effect also linked to catecholamines (39) , and to improve swim time in hypothermic rats, given alone or in combination with catecholamine releasing agents (e.g. amphetamine; swim time provides a measure of ''behavioral despair,'' a preclinical measure useful in assessing the antidepressant efficacy of drugs) (40) . Although this latter effect in rats implied that Tyr might be useful in the treatment of depression (by raising catecholamine synthesis and release), the amino acid did not show a positive effect when tested in a double-blind study in depressed human subjects (41) . Tyr administration to rats has been shown to increase neuronal catecholamine release in corpus striatum (DA) (42) and hippocampus (NE) (40) using in vivo microdialysis.
More recently, functional effects have been studied in relation to rapid reductions in brain Tyr levels using a treatment that reduces Tyr transport into brain. Tyr is transported across the BBB by a carrier that it shares with a number of other LNAA, including tryptophan, Phe, and the branched-chain amino acids (leucine, isoleucine, and valine). Because this LNAA carrier is competitive and plasma concentrations of the LNAA approximate their K m for the carrier (43) , raising the blood levels of 1 or more LNAA can reduce the uptake into brain of other LNAA and lower their brain concentrations. Thus, reducing Tyr levels in brain can be accomplished by providing an oral dose of the LNAA lacking Tyr and Phe (Phe is immediately hydroxylated to Tyr in the liver). In practice, a mixture has been used that contains amino acids in addition to the LNAA, because this combination lowers plasma concentrations of Tyr (an effect originally unanticipated) while raising those of the other LNAA, thus enhancing the antagonism of competitive Tyr transport across the BBB (44, 45) . When this mixture of amino acids was given to rats orally, circulating Tyr concentrations declined rapidly, whereas those of the other LNAA rose, producing a marked reduction in brain Tyr concentration that persisted for several hours. Association with these changes are reductions in Tyr hydroxylation rate and DA turnover in brain regions (44, 45) . For example, we observed this treatment to reduce Tyr hydroxylation rate in retina and hypothalamus ( Table 5 ) and others have observed this effect in other brain regions into which catecholamine terminals project (corpus striatum, nucleus accumbens, prefrontal cortex, and hippocampus) (20) . Some evidence suggests that this Tyr depletion paradigm may also work in humans to reduce DA release; the effect is inferred from a change in 11 C-raclopride binding in corpus striatum, using positron emission tomography (46) (raclopride is a DA receptor ligand). In rats, Tyr depletion by itself does not appear to reduce DA (prefrontal cortex) or NE (hippocampus) release, measured using in vivo microdialysis (20, 47) . However, it does reduce the increase in DA and NE release produced by drugs that either block catecholamine reuptake or receptors (20, 47) and attenuates in rats the behavioral activation produced by amphetamine, a catecholamine-releasing agent (48) .
The Tyr depletion paradigm, when applied to humans, not only seems to moderate striatal DA release (46) , but also produces behavioral and physiological effects in humans consistent with reduced DA release. For example, in normal humans, Tyr depletion increases plasma prolactin concentrations (an effect expected of reduced DA release) (49) , impairs features of spatial recognition memory and performance (49) , and attenuates subjective psychostimulant effects of amphetamine (50, 51) . Tyr depletion has also been reported to reduce clinical ratings of manic symptoms in patients diagnosed with mania (51) and to lower some indices of mood (and promote apathy) in normal subjects that are reputedly consistent with DA depletion (52, 53) .
Summary and conclusions
A considerable body of data supports the links between Tyr concentrations in catecholamine neurons in brain/retina, Tyr hydroxylation rate, and overall catecholamine synthesis and neuronal release. Moreover, a number of physiological and behavioral functions are predictably modified as a result. These relations are thought to exist only in active neurons. Despite the convincing findings, however, this substrate-product relation has never been reconciled with the observation that the K m of TH for Tyr is considerably below endogenous Tyr concentrations. TH should thus be almost fully saturated with substrate; based on this fact alone, one would not predict that raising Tyr concentrations would stimulate Tyr hydroxylation. Neuronal activation, a precondition for Tyr to be able to influence hydroxylation rate, does not increase Tyr K m [e.g. (6, 54) ]. Reduced substrate affinity is thus not an explanation. The only other possible explanation might be a reduction in Tyr concentrations in the vicinity of TH molecules when neurons have been activated and Tyr hydroxylation rate markedly increased. Whereas some data suggest that such might be the case (55) , other data disagree [e.g. Tyr levels in PC-12 cells show no obvious reduction in high potassium vs. low potassium medium; hydroxylation rate is markedly stimulated in high potassium (35) ]. Hence, an exact accounting of the mechanism by which changes in Tyr concentrations modify hydroxylation rate and catecholamine synthesis has yet to be provided. An explanation is also lacking that resolves the conflict between the concept of substrate inhibition of TH by Tyr and the ability of increases in Tyr concentration to stimulate Tyr hydroxylation rate.
Phe is also a substrate for TH. However, based on PC-12 cell studies, Tyr is the preferred substrate, except when Tyr concentrations are unusually low, a phenomenon unlikely to occur physiologically (because in mammals, ingested Phe is rapidly hydroxylated to Tyr in the liver and provided to the circulation). Hence, physiologically, DOPA synthesis is likely to derive primarily from the hydroxylation of Tyr, not Phe. Phe has been argued to be an inhibitor of TH in vivo (56) . And yet, the evidence is very weak that Phe inhibits TH; indeed, evidence is much stronger that Phe does not inhibit TH, even at extremely high concentrations. Even when apparent inhibition of DOPA synthesis can be linked to high Phe concentrations, the Phe concentrations achieved are considerably higher than even those extremely high values observed in the brains of patients with classical PKU in whom catecholamine production is diminished. One wonders what the mechanism might be that accounts for diminished catecholamine production in classical PKU, because the link to high Phe concentrations is not convincing.
Finally, all studies demonstrating functional effects of Tyrrelated changes in catecholamine production have been pharmacologic. A physiological function has yet to be demonstrated for this relation. The most attractive candidate is chronic protein ingestion and selection, because Tyr concentrations and catecholamine synthesis vary directly with protein intake over a range of intakes that brackets the animal's protein requirement. Hence, the hypothesis is that through Tyr-driven changes in catecholamine production/release, the brain can monitor adequacy of protein intake and adjust protein-seeking behavior when these biochemical indices of protein intake fall below requirement values. However, an examination of this putative chemical-functional linkage appears presently to be impossible in the laboratory in rats or primates, because these animals willingly ingest levels of protein vastly in excess of their requirement (57) when in captivity, something they do not do in their native environments. It is currently unknown why laboratory animals willingly consume such high levels of protein in their diets, particularly because essential amino acids are metabolized, once ingested, when protein intake exceeds requirements (i.e. there is no obvious metabolic benefit) (58) . Either an appropriate study needs to be designed that can be conducted in animals in their natural habitats or the Food-deprived male rats were intubated in the morning with the indicated treatment (10 ml/kg). Ninety minutes later, they received m-hydroxybenzylhydrazine (100 mg/kg ip) and were killed 30 min thereafter. One group received water only (water control); the complete mixture group received a mixture of amino acids including Tyr and Phe; the Tyr depletion mixture group received the complete mixture minus Tyr and Phe. The complete amino acid mixture contained (grams/liter, in water): L-Phe (9), L-Tyr (9), Trp (6.4), L-Leu (4), L-Ile (8), L-Val (10), L-Met (8), L-His (4), L-Thr (7), L-Gly (60), L-Lys (20) , and L-Arg (0.8). Data are means 6 SEM, n ¼ 8/group; by ANOVA, treatment effects were observed for each variable, P , 0.01; *P , 0.05 compared with water control group, **P , 0.05, compared with control or complete mixture groups (Newman-Keuls test). Adapted from (45) .
explanation found and corrected regarding the abnormality of the environment in which laboratory animals are placed that leads to such unphysiologic protein-seeking behavior.
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